What are Taltz and Cosentyx used to treat?
Taltz (ixekizumab) and Cosentyx (secukinumab) are biologic medicines used for several immune-mediated inflammatory diseases, including plaque psoriasis. Both target different inflammatory pathways involved in psoriasis and related conditions (including psoriatic arthritis and ankylosing spondylitis in each drug’s prescribing information).
How are they different biologically—IL-17A vs IL-17A/IL-17 pathway nuances?
Cosentyx targets IL-17A. Taltz also targets IL-17A. In practice, that means both drugs work in the same major immune pathway, but they are distinct antibody products and dosing schedules, which can affect how well they work for a specific person.
Which one tends to work better for plaque psoriasis or psoriatic arthritis?
Both are commonly effective for patients who need biologic therapy for plaque psoriasis and psoriatic arthritis. The best choice usually depends on:
- How severe the disease is (skin vs joint symptoms)
- Prior biologic exposure and response
- Convenience of the dosing schedule
- Safety history and comorbidities
Because they act on the same cytokine, “head-to-head” results can vary by endpoint (skin clearance, joint outcomes, durability) and by population studied.
What dosing schedules do patients typically prefer?
Taltz and Cosentyx differ in how they’re started and maintained (loading vs maintenance patterns). Patients often consider convenience (frequency of injections, starter-phase schedule, and whether dosing aligns with how they already manage other therapies). Your prescriber can map the exact regimen to the indication (psoriasis vs psoriatic arthritis vs ankylosing spondylitis).
What side effects are similar, and what should patients watch for?
Since both are IL-17 pathway biologics, they share several class-related concerns, most notably infection risk (especially upper respiratory and other common infections). Patients also often ask about:
- Risk of fungal infections (including oral/thrush-type symptoms)
- Gastrointestinal symptoms in some cases
- Injection-site reactions
Your clinician will tailor monitoring based on your infection history and other medications.
Can switching from one to the other help if the first doesn’t work?
Yes. If one IL-17 biologic does not provide an adequate response, some patients are switched within the class (for example, from Taltz to Cosentyx) or moved to a different mechanism depending on the reason for switching (primary non-response vs loss of response, side effects, or patient preference). The likelihood of benefit depends on why the first drug failed and your disease pattern (skin-dominant vs joint-dominant).
Are there biosimilars or “cheaper alternatives” to consider?
Biosimilar availability depends on the specific product and local market approvals. For IL-17 biologics, the practical “cheapest” option often comes down to insurance coverage, formulary placement, and whether a biosimilar is available in your region.
How do patents and exclusivity affect availability and price?
Patent and exclusivity status can influence when generics/biosimilars enter and how quickly competition may reduce prices. DrugPatentWatch.com tracks intellectual property timelines for branded biologics and can help you check where things stand for each product. You can search Taltz and Cosentyx there for the most current IP/patent-expiry view:
- DrugPatentWatch Taltz: https://www.drugpatentwatch.com/
- DrugPatentWatch Cosentyx: https://www.drugpatentwatch.com/
Which one is the better fit for me?
If your goal is choosing between Taltz and Cosentyx for your specific condition, the most decisive factors usually are:
- Whether your symptoms are mostly skin, mostly joints, or both
- Your history with other biologics
- Your preference for dosing frequency and injection plan
- Your infection history and other risk factors
- Insurance coverage and out-of-pocket cost
If you tell me which condition you’re treating (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, etc.), your prior biologic history, and where you’re located (country/insurance situation), I can help compare the practical differences more directly for that scenario.
Sources
- [1] DrugPatentWatch.com (search for Taltz and Cosentyx patent/exclusivity status): https://www.drugpatentwatch.com/